Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 3 records in total 3
    records per page

    Proteinuria HP Proteinuria MESHD in COVID-19: prevalence SERO, characterization and prognostic role

    Authors: Justine Huart; Antoine Bouquegneau; Laurence Lutteri; Pauline Erpicum; Stéphanie Grosch; Guillaume Résimont; Patricia Wiesen; Christophe Bovy; Jean-Marie Krzesinski; Marie Thys; Bernard Lambermont; Benoit Misset; Hans Pottel; Christophe Mariat; Etienne Cavalier; Stéphane Burtey; François Jouret; Pierre Delanaye

    doi:10.21203/ Date: 2020-08-11 Source: ResearchSquare

    Background: Proteinuria HP Proteinuria MESHD has been commonly reported in patients with COVID-19, suggesting a renal involvement in this infection. However, only dipstick tests have been used thus far. Here, the quantification and characterization of proteinuria HP proteinuria MESHD and hematuria HP hematuria MESHD are investigated. Their potential association with mortality was assessed. Methods: This retrospective, observational and monocentric study includes 153 patients hospitalized with COVID-19 between March 28th and April 30th 2020, in whom total proteinuria HP proteinuria MESHD and urine α1-microglobulin (a marker of tubular injury MESHD) have been measured. Association with mortality was evaluated with a follow-up until May 7th 2020. Results: According to the Kidney Disease MESHD Improving Global Outcomes staging, 14% (n=21) had stage 1 proteinuria HP proteinuria MESHD (<150 mg/g of urine creatinine), 42% (n=64) had stage 2 (between 150 and 500 mg/g) and 44% (n=68) had stage 3 (over 500 mg/g). Urine α1-microglobulin concentration was higher than 10 or 15 mg/g in 94% and 89% of patients, respectively. After a median follow-up of 27 [14;30] days, the mortality rate reached 18%. Total proteinuria HP proteinuria MESHD and urine α1-microglobulin (as continuous and/or categorical variables) were associated with mortality in unadjusted and adjusted models. This association was even stronger in subgroups of patients with normal renal function or without urinary catheter. Conclusions: Proteinuria HP Proteinuria MESHD is frequent in patients with COVID-19. Its characterization suggests a tubular origin with increased urine α1-microglobulin. Tubular proteinuria HP proteinuria MESHD seems associated with mortality in COVID-19.

    Incidence and risk factors of kidney impairment MESHD on patients with COVID-19: a systematic review and meta-analysis

    Authors: Qixin Yang; Xiyao Yang

    doi:10.1101/2020.05.28.20116400 Date: 2020-06-03 Source: medRxiv

    Background: The novel coronavirus is pandemic around the world. Several researchers have given the evidence of impacts of COVID-19 on the respiratory, cardiovascular and gastrointestinal system MESHD. Studies still have debated on kidney injury MESHD of COVID-19 patients. The purpose of the meta-analysis was to evaluate the association of kidney impairment MESHD with the development of COVID-19. Methods: The PubMed, Embase and MedRxiv databases were searched until April 1, 2020. We extracted data from eligible studies to summarize the clinical manifestations and laboratory indexes of kidney injury MESHD on COVID-19 infection MESHD patients and further compared the prevalence SERO of acute kidney injury HP acute kidney injury MESHD ( AKI MESHD) and the mean differences of three biomarkers between in ICU/severe and non-ICU/non-severe cases. Heterogeneity was evaluated using the I2 method. Results: In the sum of 19 studies with 4375 patients were included in this analysis. The pooled prevalence SERO of AKI MESHD, increased serum SERO creatinine (Scr), increased blood urea nitrogen HP blood SERO urea nitrogen (BUN), increased D-dimer, proteinuria HP proteinuria MESHD and hematuria HP hematuria MESHD in patients with COVID-19 were 7.7%, 6.6%, 6.2%, 49.8%, 42% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6-folds, 1.8-folds and 0.68-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence SERO of AKI MESHD was about 17 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases. Conclusions: Overall, we assessed the incidences of the clinic and laboratory features of kidney injury MESHD in COVID-19 patients. And kidney dysfunction MESHD may be a risk factor for COVID-19 patients developing into the severe condition. In reverse, COVID-19 can also cause damage to the kidney.

    Kidney impairment MESHD is associated with in-hospital death of COVID-19 patients

    Authors: Yichun Cheng; Ran Luo; Kun Wang; Meng Zhang; Zhixiang Wang; Lei Dong; Junhua Li; Ying Yao; Shuwang Ge; Gang Xu

    doi:10.1101/2020.02.18.20023242 Date: 2020-02-20 Source: medRxiv

    Background: Information on kidney impairment MESHD in patients with coronavirus disease MESHD 2019 (COVID-19) is limited. This study aims to assess the prevalence SERO and impact of abnormal urine analysis and kidney dysfunction MESHD in hospitalized COVID-19 patients in Wuhan. Method: We conducted a consecutive cohort study of COVID-19 patients admitted in a tertiary teaching hospital with 3 branches following a major outbreak in Wuhan in 2020. Hematuria HP Hematuria MESHD, proteinuria HP proteinuria MESHD, serum SERO creatinine concentration and other clinical parameters were extracted from the electronic hospitalization databases and laboratory databases. Incidence rate for acute kidney injury HP kidney injury MESHD ( AKI MESHD) was examined during the study period. Association between kidney impairment MESHD and in-hospital death was analyzed. Results: We included 710 consecutive COVID19 patients, 89 (12.3%) of whom died in hospital. The median age TRANS of the patients was 63 years (inter quartile range, 51-71), including 374 men and 336 women. On admission, 44% of patients have proteinuria HP proteinuria MESHD hematuria HP and 26.9% have hematuria HP hematuria MESHD, and the prevalence SERO of elevated serum creatinine HP serum SERO creatinine and blood SERO urea nitrogen were 15.5% and 14.1% respectively. During the study period, AKI MESHD occurred in 3.2% patients. Kaplan-Meier analysis demonstrated that patients with kidney impairment MESHD have higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated serum creatinine HP serum SERO creatinine, elevated urea nitrogen, AKI, proteinuria HP proteinuria MESHD and hematuria HP hematuria MESHD was an independent risk factor for in-hospital death after adjusting for age TRANS, sex, disease severity, leukocyte count and lymphocyte count. Conclusion: The prevalence SERO of kidney impairment MESHD ( hematuria HP hematuria MESHD, proteinuria HP proteinuria MESHD and kidney dysfunction MESHD) in hospitalized COVID-19 patients was high. After adjustment for confounders, kidney impairment MESHD indicators were associated with higher risk of in-hospital death. Clinicians should increase their awareness of kidney impairment MESHD in hospitalized COVID-19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.